Erratum: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells (Journal of Molecular Medicine (2012) 90:1 (45-54) DOI 10.1007/s00109-011-0805-8);Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

Journal of Molecular Medicine

Volumn 90, Issue 1, 2012, Pages 45-54

  Befani, Christina D ^a   Vlachostergios, Panagiotis J ^b   Hatzidaki, Eleana ^b   Patrikidou, Anna ^b   Bonanou, Sophia ^a   Simos, George ^a,c   Papandreou, Christos N ^b   Liakos, Panagiotis ^a,c  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

Bortezomib; HIF 1 ; P44 42 MAPK signaling pathway; PI3K Akt mTOR; Prostate cancer

Indexed keywords

BORTEZOMIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN;

ARTICLE; BIOACCUMULATION; CANCER CELL; CONTROLLED STUDY; DRUG EFFECT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84857368471     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1030-4     Document Type: Erratum

References (35)

1. Adams J, Kauffman M (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 22:304-411
2. Papandreou CN, Logothetis CJ (2004) Bortezomib as a potential treatment for prostate cancer. Cancer Res 64:5036-5043 (Pubitemid 39006513)
3. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A et al (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66:184-191 (Pubitemid 43166024)
4. Veschini L, Belloni D, Foglieni C, Cangi MG, Ferrarini M, Caligaris-Cappio F, Ferrero E (2007) Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 109:2565-2570 (Pubitemid 46425903)
5. Semenza GL (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19:12-16
6. Jiang BH, Liu LZ (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102:19-65
7. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, VandeWoude GF, Ahn NG (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966-970 (Pubitemid 24281496)
8. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J (2003) MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278:14013-14019 (Pubitemid 36799945)
9. Richard DE, Berra E, Gothié E, Roux D, Pouysségur J (1999) p42/p44 MAP kinases phosphorylate hypoxia inducible factor 1 alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274:32631-32638
10. Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A, Georgatsou E, Bonanou S, Simos G (2006) Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 281:33095-33106 (Pubitemid 46043259)
11. Mylonis I, Chachami G, Paraskeva E, Simos G (2008) Atypical CRM1-dependent nuclear export signal mediates regulation of hypoxia-inducible factor-1alpha by MAPK. J Biol Chem 283:27620-27627
12. Triantafyllou A, Mylonis I, Simos G, Bonanou S, Tsakalof A (2008) Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. Free Radic Biol Med 44:657-670
13. Shin DH, Chun YS, Lee DS, Huang LE, Park JW (2008) Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia inducible factor-1. Blood 111:3131-3136
14. Kaluz S, Kaluzova M, Stanbridge EJ (2006) Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1a C-terminal activation domain. Mol Cell Biol 26:5895-5907 (Pubitemid 44134343)
15. Birle DC, Hedley DW (2007) Suppression of the hypoxiainducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 67:1735-1743 (Pubitemid 46383400)
16. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ (2009) Control of HIF-1alpha expression by eIF2 alpha phosphorylationmediated translational repression. Cancer Res 69:1836-1843
17. Patrikidou A, Vlachostergios PJ, Voutsadakis IA, Hatzidaki E, Valeri RM, Destouni C, Apostolou E, Daliani D, Papandreou CN (2011) Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int 11:13
18. Ikezoe T, Yang Y, Saito T, Koeffler HP, Taguchi H (2004) Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 95:271-275 (Pubitemid 38489096)
19. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ (2005) Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 56:46-54 (Pubitemid 41201755)
20. Kimbro KS, Simons JW (2006) Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13:739-749 (Pubitemid 44763255)
21. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830-5835
22. Salnikow K, Costa M, Figg WD, Blagosklonny MV (2000) Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res 60:5630-5634
23. Sheflin LG, Zou AP, Spaulding SW (2004) Androgens regulate the binding of endogenous HuR to the AU-rich 3'UTRs of HIF-1alpha and EGF mRNA. Biochem Biophys Res Commun 322:644-651 (Pubitemid 39490351)
24. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW (2003) Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9:2416-2425 (Pubitemid 36842080)
25. Mitani T, Yamaji R, Higashimura Y, Harada N, Nakano Y, Inui H (2011) Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1α in a low androgen environment. J Steroid Biochem Mol Biol 123:58-64
26. Papatsoris AG, Karamouzis MV, Papavassiliou AG (2007) The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol Cancer Ther 6:811-819 (Pubitemid 46554551)
27. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL (2008) Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68:6698-6707
28. Codony-Servat J, Tapia MA, Bosch M et al (2006) Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5:665-675
29. Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, Schenkein D, Pandiella A, San Miguel JF (2005) Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 114:665-667 (Pubitemid 40349629)
30. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC (2003) Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22:8386-8393 (Pubitemid 37523890)
31. Mylonis I, Lakka A, Tsakalof A, Simos G (2010) The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. Biochem Biophys Res Commun 398:74-78
32. Hur E, Chang KY, Lee E, Lee SK, Park H (2001) Mitogenactivated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol Pharmacol 59:1216-1224 (Pubitemid 32381601)
33. Zhong H, Semenza GL, Simons JW, De Marzo AM (2004) Upregulation of hypoxia-inducible factor 1a is an early event in prostate carcinogenesis. Cancer Detection and Prevention 28:88-93 (Pubitemid 38448745)
34. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL (2005) The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11:7658-7663 (Pubitemid 41611607)
35. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, GeraldWL, Cordon-Cardo C, Abate-Shen C (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118:3051-3064